Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.59 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29448257 | 0.87 | L3MBTL1 (0.62) | GAACA12CA1CA2CA7 | |
| SCHEMBL391334 | 0.87 | L3MBTL1 (0.62) | GAACA12CA1CA2CA7 | |
| SCHEMBL1403472 | 0.86 | ALDH1A1 (0.56) | GAAKMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL30203403 | 0.86 | ALDH1A1 (0.56) | GAAKMT2AALDH1A1SMN1; SMN2MEN1 | |
| Methane SCHEMBL27588822 | 0.85 | ALDH1A1 (0.54) | GAAKMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL6960199 | 0.83 | KDM4E (0.55) | KMT2AALDH1A1GPR35SMN1; SMN2MEN1 | |
| SCHEMBL3835248 | 0.83 | MEN1 (0.51) | GAACA12CA1CA2CA7 | |
| SCHEMBL1163261 | 0.83 | ADRB2 (0.56) | GAAKMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL5925545 | 0.83 | SMN1; SMN2 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16423530 | 0.83 | ALDH1A1 (0.51) | GAAKMT2AALDH1A1GPR35SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101348444-B | Preparation of 2-ethoxy-4-acetaminobenzoic acid methyl ester | ZHEJIANG ESIGMA ANIMAL HEALTH CO LTD | 2012-01-11 | — | — | CN | claimed |
| CN-101348444-A | Preparation of 2-ethoxy-4-acetaminobenzoic acid methyl ester | ZHEJIANG HUINENG ANIMALS LEECH (CN) | 2009-01-21 | — | — | CN | claimed |
| US-20060110743-A1 | Drug evolution: drug design at hot spots | KONISHI YASUO | 2006-05-25 | — | — | US | claimed |
| WO-2002095393-A2 | DRUG EVOLUTION: DRUG DESIGN AT HOT SPOTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2002-11-28 | — | — | WO | claimed |
| CN-122094675-A | Deuterated organic compounds and use thereof | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4734983-A2 | DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF | Engrail Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250353862-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4547671-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119859155-A | Tri-fused ring derivative inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-04-22 | — | — | CN | disclosed |
| WO-2025010255-A2 | DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF | ENGRAIL THERAPEUTICS, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| CN-119255997-A | Modulators of c-MYC mRNA translation and their use in the treatment of cancer | 艾尼莫生物科技公司 | 2025-01-03 | — | — | CN | disclosed |
| WO-2024010761-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| WO-2000064864-A9 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RES CAMPAIGN TECH (GB) | 2001-12-27 | — | — | WO | disclosed |
| WO-2000064864-A1 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-11-02 | — | — | WO | disclosed |
| EP-0133423-B1 | USE OF 4,5'-AZO-BIS-SALICYLIC ACID FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY DISORDERS IN THE INTESTINE | PHARMACIA AB (SE) | 1987-11-25 | — | — | EP | disclosed |
| US-4591584-A | ANTIINFLAMMATORY AGENTS; GASTRO INTESTINAL DISORDERS | PHARMACIA AB (SE) | 1986-05-27 | — | — | US | disclosed |
| EP-0145777-A1 | AZO-BIS-SALICYLIC ACID AND SALT THEREOF, PHARMACEUTICAL FORMULATIONS AND USES OF SAID ACID AND SALT, AND PRODUCTION OF THE ACID | PHARMACIA AB (SE) | 1985-06-26 | — | — | EP | disclosed |
| EP-0133423-A1 | Use of 4,5'-azo-bis-salicylic acid for the manufacture of a medicament for the treatment of inflammatory disorders in the intestine | PHARMACIA AB (SE) | 1985-02-20 | — | — | EP | disclosed |
| WO-1985000013-A1 | AZO-BIS-SALICYLIC ACID AND SALT THEREOF, PHARMACEUTICAL FORMULATIONS AND USES OF SAID ACID AND SALT, AND PRODUCTION OF THE ACID | PHARMACIA AB (SE) | 1985-01-03 | — | — | WO | disclosed |
| US-4006239-A | Benzoic acid amides for mycobacterium infections | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353862-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | GAA 3895/4885CA12 4693/4885CA1 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.